Osteoporosis is a medical condition in which new calcium deposits in bone tissue cannot keep up with old bone calcium removal ...

Implementing opportunistic computed tomography (CT) bone density screening could increase the osteoporosis screening rate, ...

The global osteoporosis drugs market size was valued at USD 14.90 billion in 2024 and is projected to reach USD 15.39 billion ...

Women with osteoporosis have at least a 50% chance of reaching their target bone mineral density at 3 years if they have a ...

A new study published in the journal of BMC Gasteroenterology found that patients with the liver cirrhosis had higher risk of ...

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).

The "Osteoporosis_Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report provides an overview of Osteoporosis Clinical ...

In a study published in a 2024 issue of the American Journal of Obstetrics & Gynecology, researchers predicted that for most ...

Romosozumab vs bisphosphonate use was not linked to increased CVD risks among patients with osteoporosis, challenging past concerns over its cardiovascular safety.

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for ...

The UK osteoporosis fracture healing market is on a steady growth trajectory, with market size expected to reach USD 738.6 million by 2025. Driven by an increasing prevalence of osteoporosis-related ...